DOXYCYCLINE FOR USE IN DIABETIC RETINOPATHY

According to this study in JAMA Ophthalmology:

To our knowledge, this is the first observation suggesting a link between a low-dose oral anti-inflammatory agent and subclinical improvement in inner retinal function. Oral doxycycline may be a promising therapeutic strategy targeting the inflammatory component of diabetic retinopathy. Furthermore, study results suggest that frequency doubling perimetry, which primarily measures inner retinal function, is responsive to intervention and may be a useful clinical trial end point for proof-of-concept studies in patients with diabetic retinopathy